Status:
COMPLETED
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The objective of this study was to measure the continued efficacy of apomorphine after previous exposure of at least three months duration.
Detailed Description
This was a prospective, double-blind, randomized, placebo-controlled, crossover desigh, multicenter study of the safety and effectiveness of subcutaneous apomorphine treatment. Patients received both ...
Eligibility Criteria
Inclusion
- Patients diagnosed with idiopathic Parkinson's Disease and classified as stage II-IV of the Hoehn and Yahr scale for staging the severity of Parkinson's Disease
- Patients must have been on an optimally maximized oral therapy regimen including levodopa/decarboxylase inhibitors in either immediate or delayed release forms, plus at least one direct acting oral dopamine agonist for at least 30 days prior to randomization
- Patients must have been receiving apomorphine subcutaneous injections for rescue therapy for "Off" events for at least three months with an average dosing requirement of at least 2 doses per day over the week prior to enrollment with a dose of less than 11 mg
Exclusion
- Patients under medical therapy for clinically significant psychoses or dementia not related to ingestion of antiparkinson medications. (Patients with hallucinations or other central adverse reactions associated solely with antiparkinson medications were not excluded.)
- Patients with a history of drug or alcohol dependency within one year prior to study enrollment
- Patients with unstable and clinically significant disease of cardiovascular (including orthostatic hypotension), hematologic (including Coombs' positive hemolytic anemia), hepatic, renal, metabolic, respiratory, gastrointestinal or endocrinological systems or neoplasm within the threemonths before the start of the study.
- Patients with a history of allergy or intolerance to morphine or its derivatives, sulfur, sulfur containing medication, sulfites, domperidone, trimethobenzamide or other anticholinergics.
- Patients treated with experimental agents (other than apomorphine intermittent subcutaneous injections) within 3 months before study entry, experimental agents were defined on the basis of the regulatory status in the country of patient observation, or with other disallowed medications
- Patients whose apomorphine regimen was characterized by continuous infusion or by administration methods other than intermittent subcutaneous injection.
- Patients who could not or would not sign an informed consent form.
Key Trial Info
Start Date :
September 1 1999
Trial Type :
INTERVENTIONAL
End Date :
November 1 1999
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00200512
Start Date
September 1 1999
End Date
November 1 1999
Last Update
December 16 2005
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Walton Centre for Neurology and Neurosurgery
Liverpool, United Kingdom
2
The Morriston Hospital
Swansea, United Kingdom